1,380 assets in Cancer

Therapeutic assets addressing Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cmp 001 Cancer	Pfizer	P3	B (60)
Cytarabine Cancer	Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.	P3	B (60)
Dabrafenib Cancer	Cancer Research UK	P3	B (60)
Disitamab Vedotin Cancer	LaNova Medicines Limited	P3	B (60)
Enfortumab Vedotin (Fully Human Monoclonal Antibody Conjugated To A Cytotoxic Agent Monomethyl Auristatin E (Mmae) Targeting Nectin-4) Cancer	Astellas Pharma Global Development, Inc.	P2	B (60)
Fruquintinib Cancer	Fudan University	P2	B (60)
Hrs-7058 Cancer	Shandong Suncadia Medicine Co., Ltd.	P2	B (60)
Infliximab Cancer	M.D. Anderson Cancer Center	P2	B (60)
Lenvatinib Cancer	LaNova Medicines Limited	P2	B (60)
Lorlatanib Cancer	Pfizer	P3	B (60)
Methylene Blue Cancer	Mayo Clinic	P3	B (60)
Osimertinib Cancer	Shanghai Hengrui Pharmaceutical Co., Ltd.	P4	B (60)
Pembrolizumab Cancer	InSilico Medicine Hong Kong Limited	P4	B (60)
Puxitatug Samrotecan Cancer	AstraZeneca	P3	B (60)
Regorafenib Cancer	West China Hospital	P2	B (60)
Tislelizumab Cancer	LaNova Medicines Limited	P3	B (60)
Abemaciclib Cancer	University Health Network, Toronto	P2	B (59)
Adriamycin Cancer	Junpeng Wang	P3	B (59)
Aspirin Cancer	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	P3	B (59)
Eribulin Cancer	GI Innovation, Inc.	P2	B (59)
Eribulin Monomethanesulfonate Cancer	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P1/2	B (59)
Lurbinectedin Cancer	Jazz Pharmaceuticals	P2	B (59)
Megestrol Acetate Cancer	Sixth Affiliated Hospital, Sun Yat-sen University	P3	B (59)
(±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone Cancer	Ankara City Hospital Bilkent	P3	B (58)
Adagrasib Cancer	Bristol-Myers Squibb	P2	B (58)
Atezolizumab Cancer	Exelixis	P3	B (58)
Cetuximab Cancer	National Cancer Institute (NCI)	P3	B (58)
Crizotinib Cancer	Canadian Cancer Trials Group	P3	B (58)
Durvalumab Cancer	Inimmune Corporation	P2	B (58)
Everolimus Cancer	SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany	P3	B (58)
Fulvestrant Cancer	BeOne Medicines	P3	B (58)
Itraconazole Cancer	Hansoh BioMedical R&D Company	P3	B (58)
Letrozole Cancer	Barbara Ann Karmanos Cancer Institute	P3	B (58)
Marcaine Cancer	Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)	P2	B (58)
Mercaptopurine Anhydrous Cancer	The First Affiliated Hospital with Nanjing Medical University	P3	B (58)
Palbociclib Cancer	Bristol-Myers Squibb	P2	B (58)
Pucotenlimab Cancer	Taizhou Hanzhong biomedical co. LTD	P3	B (58)
Sirolimus Cancer	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	P2	B (58)
Tipiracil Cancer	Parabilis Medicines, Inc.	P3	B (58)
Trastuzumab Cancer	University Health Network, Toronto	P3	B (58)
Trifluridine Cancer	Parabilis Medicines, Inc.	P3	B (58)
Alectinib Cancer	Cancer Research UK	P2/3	B (57)
Cefepime Cancer	M.D. Anderson Cancer Center	P2	B (57)
ima203 Cancer	Immatics US, Inc.	P1/2	B (57)
Imipenem Cancer	M.D. Anderson Cancer Center	P2	B (57)
Letermovir Cancer	Children's Oncology Group	P3	B (57)
Lifileucel Cancer	Hervor Therapeutics	P2	B (57)
Linezolid Cancer	M.D. Anderson Cancer Center	P2	B (57)
Nbm-Bmx Cancer	Novelwise Pharmaceutical Corporation	P1/2	B (57)
Talazoparib Cancer	National Cancer Institute (NCI)	P3	B (57)

Showing 51 to 100 of 1,380 assets

PreviousPage 2 of 28Next